Preview Mode Links will not work in preview mode

BrainWaves: A Neurology Podcast


Mar 29, 2018

What does a brain look like in a patient with a functional movement disorder? Pretty normal, it turns out. But beneath the normal anatomy is a storm of aberrant signaling. Dr. Mark Hallett, Chief of the Human Motor Control Section of the NIH, describes the underlying neurophysiology in this spectrum of disorders.

Produced by James E. Siegler. Music by Damiano Baldoni, Kevin MacLeod, Ondrosik, and the Philadelphia String Quartet. Voiceover by Erika Mejia. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making.

REFERENCES

  1. Maurer CW, LaFaver K, Ameli R, Epstein SA, Hallett M and Horovitz SG. Impaired self-agency in functional movement disorders: A resting-state fMRI study. Neurology. 2016;87:564-70.
  2. Vuilleumier P, Chicherio C, Assal F, Schwartz S, Slosman D and Landis T. Functional neuroanatomical correlates of hysterical sensorimotor loss. Brain. 2001;124:1077-90.
  3. Nahab FB, Kundu P, Gallea C, Kakareka J, Pursley R, Pohida T, Miletta N, Friedman J and Hallett M. The neural processes underlying self-agency. Cereb Cortex. 2011;21:48-55.

DISCLOSURES

Dr. Hallett receives funding from the Intramural program of the National Institute of Neurological Disorders and Stroke. No relevant conflicts of interest are present. He serves as Chair of the Medical Advisory Board for and receives honoraria and funding for travel from the Neurotoxin Institute. He may accrue revenue on US Patent: Immunotoxin (MAB-Ricin) for the treatment of focal movement disorders, and US Patent: Coil for Magnetic Stimulation and methods for using the same (H-coil); in relation to the latter, he has received license fee payments from the NIH (from Brainsway) for licensing of this patent. Supplemental research funds have been granted by BCN Peptides, S.A., for treatment studies of blepharospasm; Medtronics, Inc., for studies of deep brain stimulation; UniQure for a clinical trial of AAV2-GDNF for Parkinson Disease; Merz for treatment studies of focal hand dystonia; and Allergan for studies of methods to inject botulinum toxins. Jim is lucky enough to have no relevant competing financial interests.